Rebates In Part D: HHS Argues Scrutiny Of Impact On Formularies, Beneficiaries Not Needed Now
New GAO recommendations springing from recent Medicare Part D cost and access trends related to rebates may not be relevant going forward because the IRA price negotiation program and benefit redesign will significantly change the landscape, HHS says.
You may also be interested in...
Commission pursued merger challenge to halt pharma practices it believes can stifle competition and keep drug prices high. Other large biopharma transactions may face similar challenges as FTC pursues its new merger program.
Long-awaited list has a couple of surprises that are expected to face biosimilar competition either before negotiated prices are implemented in 2026 or during that year.
A new biosimilar payment boost, a true, but more limited patient-directed pass-through rebate plan, and product hopping legislation are among the more than two-dozen amendments that could be added to the Senate Finance Committee’s PBM reform package.